“There’s a way to do it better. Find it.“
Thomas Edison
I2F
I2F is our flagship medical device that solves a $3 Billion waste problem. The current method of plasma-derived medications by IV infusion is inefficient and wasteful. Plasma-derived medications are very expensive and this waste can be up to 5%. I2F eliminates waste caused by foaming.
Information for Payers
Everyone wants to get what they pay for. Using the I2F ensures you and your patients are getting what you (they) pay for.
Waste is one of the largest issues in healthcare. The current method of administering plasma-derived medications via infusion remains inefficient and wasteful. We have developed a solution to this problem with a simple, yet cost effective device.
Introducing I2F
I2F offers numerous potential benefits to patients and insurance companies/payers. Its adoption can lead to considerable cost-savings, thanks to its ability to provide patients when their full dose of medication. For some illnesses, receiving the full dose of medication helps reduce hospital readmissions due to opportunistic infections.
At AII, we understand the impact waste has on the healthcare system. That’s why we have developed this device, a true game-changer in the infusion industry. The inventor of this device has been a nurse for nearly 30 years.
The problem was observed while working with immunosuppressed patients receiving IVIG infusions. The process of pooling the medications into a pooling bag caused the medication to foam in the glass bottle. After the pooling of the bottle, the bottle was thrown away along with all of the foaming medication. The thoughtful nurse stored many bottles and assessed them after hours of sitting on a shelf. The medication condensed back down to liquid form. After observing this for a few years and measuring hundreds of bottles after sitting on a shelf, it was calculated that the foaming caused 2 to 5 % of waste.
In our testing, using I2F to pool medications in to an infusion bag actually saved nursing/pharmacist time too.
I2F is a single use device. Payers would pay approximately $12 per device in exchange for the patient to receive hundreds of dollars worth of medication that would have been wasted.
Another scenario of cost savings: If a patient is maintaining their IgG levels but requires an extra 5 Gram bottle for their infusions, it’s possible that the patient could maintain their IgG levels using I2F without having that extra bottle of IG since they are receiving the full amount from the other bottles. This is an example of how it would save the payers money.
Our device has been rigorously tested to meet the highest industry standards and adheres to strict quality control measures.
I2F is proudly made in the USA.